Mechanisms of interleukin-10-mediated immune suppression

Immunology

Volumn 103, Issue 2, 2001, Pages 131-136

  Akdis, Cezmi A ^a   Blaser, Kurt ^a  

^a SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CYTOKINE; INTERLEUKIN 10;

ALLERGY; CYTOKINE PRODUCTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

CYTOKINES; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; IMMUNOGLOBULIN E; INTERLEUKIN-10; T-LYMPHOCYTE SUBSETS;

EID: 0035018568     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2001.01235.x     Document Type: Review

References (67)

1. Immunoregulatory T-cell pathways
2. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off
3. Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation
4. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation
5. CD28-mediated signalling co-stimulates murine T cells and prevents induction of energy in T-cell-clones
6. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1
7. lck and ZAP-70 tyrosine kinase activities
8. An altered peptide ligand specifically inhibits Th2 cytokine synthesis by abrogating TCR signaling
9. Prevention of T cell anergy by signalling through the γc chain of the IL-2 receptor
10. Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes
11. 2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro
12. Role of IL-10 in specific immunotherapy
13. IL-10 induced anergy in peripheraI T cell and reactivation by microenvironmental cytokines: Two key steps in specific immunotherapy
14. Induction of hapten-specific tolerance by interleukin 10 in vivo
15. High levels of interleukin 10 production in vivo ate associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells
16. Maintenance of clonal anergy by endogenoasly produced IL-10
17. Control of allergic reactivity in human filariasis. Predominant localization of blocking antibody to the IgG4 subclass
18. Nasal challenge with ragweed in hay rever patients: Effect of immunotherapy
19. The effect of immunotherapy on bronchial hyper-responsiveness and eosinophil cationic protein in pollen allergic patients
20. 2 antibodies
21. Differential regulation of human T cell cytokine patterns and IgE and IgG4 responses by conformational antigen variants
22. 2 induces specific T cell anergy in bee sting allergic patients
23. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen stimulated T cell cultures
24. Insect venom immunotherapy induces interleukin-10 production anda Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects
25. Effects of peptide therapy on ex vivo T cell responses
26. Long-term clinical efficacy of grass-pollen immunotherapy
27. Glucocorticoids inhibit human antigen-specific and enhance total IgE and IgG4 production due to differential effects on T and B cells in vitro
28. 2-specific human IgE and IgG4 antibodies in vitro requires allergen-specific and non-specific activation of T and B cells
29. 2
30. 2
31. Regulation of specific immune responses by chemical and structural modifications of allergens
32. Mechanisms of allergen-specific immunotherapy
33. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding
34. Allergen immunotherapy decreases interleukin 4 production in CD4 T cells from allergic individuals
35. Immunological changes associated with immunotherapy
36. Ragweed immunotherapy decreases T cell reactivity to recombinant Amb A I.1
37. Inhibition of T cell and antibody responses to house dust mire allergen by inhalation of the dominant T cell epitope in naive and sensitized mice
38. Peripheral T cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I
39. Treatment of cat allergy with T cell reactive peptides
40. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions
41. Nasal immunotherapy in weed-induced allergic rhinitis
42. Effect of preseasonal enzyme potentiated desensitization on plasma IL-6 and IL-10 of grass pollen-sensitive asthmatic children
43. Two types of mouse T helper cell IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones
44. IL-10 inhibits cytokine production by activated macrophages
45. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes
46. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production
47. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
48. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils
49. T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma
50. Regulation of human basophil mediator release by cytokines. I. Interaction with anti-inflammatory steroids
51. The expanding universe of T-cell subsets. Th1, Th2 and more
52. Interleukin (IL) -10 Inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells
53. IL-10: A potential therapy for allergic inflammation?
54. B7/CD28-dependent IL-5 production by human resting T cells is inhibited by IL-10
55. Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils
56. CD40 expression by human peripheral blood eosinophils
57. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway
58. PI 3-kinase: Structural and functional analysis of intersubunit interactions
59. P13-kinase: A pivotal pathway in T-cell activation?
60. T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr (P) -Met-Xaa-Met motif
61. The genomic organization of the CD28 gene: Implications for the regulation of CD28 mRNA expression and heterogeneity
62. Fyn regulate CD28 binding to phosphatidiylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein -tyrosine kinase ITK. Implications for T-cell costimulation
63. IL-10 induces the tyrosine phosphorylation of Tyk2 and Jak1 and the differential assembly of STAT1α and STAT3 complexes in human T cells and monocytes
64. Functional regions of the mouse interleukin-10 receptor cytoplasmic domain
65. Interleukin-10 inhibits expression of both interferon α and interferon γ-induced genes by suppressing tyrosine phosphorylation of STAT1
66. Identification and functional characterization of a second chain of the interleukin-10 receptor complex
67. Molecular basis of T cell inactivation by CTLA-4